Document is current

Any future updates will be listed below

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

Crossref DOI link: https://doi.org/10.1186/s40064-015-1067-7

Published Online: 2015-07-03

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark